

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/608,559

Applicant: MURDIN, Andrew D. et al.

Filed: June 30, 2003

TC/A.U.: 1645

Examiner: Jennifer E. Graser

Docket No: 032931/0264

**DECLARATION PURSUANT TO 37 CFR 1.131**

I, Andrew Murdin, Director, External R&D Canada, Aventis Pasteur, hereby declare that:

1. I am an inventor in the above-identified application, and am employed by the assignee, Aventis Pasteur.

2. Details of my employment history are as follows:

Since 2002 Director, External R&D Canada, Aventis Pasteur.

1999-2002 Principal Research Scientist, Aventis Pasteur.

1997-2002 Section Head, Aventis Pasteur.

1993-2003 Project Leader (Chlamydia), Aventis Pasteur.

1990-1993 Research Scientist, Connaught Laboratories Ltd. (subsequently Pasteur Merieux Connaught, subsequently Aventis Pasteur), Toronto, Canada.

1988-1990 Post-Doctoral Research Associate, Dept. of Microbiology, State University of New York, Stony Brook, NY, USA.

1985-1987 Post-Doctoral Research Fellow, Dept. of Microbiology, University of Surrey, Guildford, Surrey, England.

1981-1985 Scientific Officer, Vaccine Research Dept., Animal Virus Research Institute, Pirbright, Surrey, England.

Details of my education are as follows:

B.Sc., University of Bath, England, 1980

Ph.D., University of Surrey, England, 1986.

Application No.: 10/608,559

3. I am an inventor of the subject matter of the following US applications:

US 60/106,034 filed October 28, 1998,  
US 60/106,039 filed October 28, 1998,  
US 60/106,042 filed October 28, 1998,  
US 60/106,044 filed October 28, 1998,  
US 60/106,072 filed October 29, 1998,  
US 60/106,073 filed October 29, 1998,  
US 60/106,074 filed October 29, 1998,  
US 60/106,087 filed October 29, 1998,  
US 60/106, 587 filed November 2, 1998,  
US 60/106, 588 filed November 2, 1998,  
US 60/106, 589 filed November 2, 1998,  
US 60/107, 034 filed November 2, 1998, and  
US 60/107, 035 filed November 2, 1998.

4. The applications identified in paragraph (3) describe 13 separate antigens from *Chlamydia pneumoniae*.

5. The 13 antigens described in the applications identified in paragraph (3) are representative of polypeptides encoded by the *Chlamydia pneumoniae* genome.

6. The applications identified in paragraph (3) describe expression of the 13 antigens in host cells, and use of these antigens as vaccines to immunize a host against Chlamydia.

Application No.: 10/608,559

7. I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Jan 1<sup>st</sup> 2004

Date

Andrew Murdin

Andrew Murdin

Director, External R&D Canada, Aventis Pasteur